Limitations, agreements, and source contact

Acalabrutinib (ACP-196) in Combination With ACP-319, for Treatment of B-Cell Malignancies · Source last updated 2025-12-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

point Of Contact

email

information.center@astrazeneca.com

organization

Acerta Pharma

phone

1-877-240-9497

title

Global Clinical Lead

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice